Synonyms: 4-C-32 | 53-32C | Ticlid®
ticlopidine is an approved drug (FDA (1991))
Compound class:
Synthetic organic
Comment: Ticlopidine is an antiplatelet drug. This compound is believed to be a prodrug, although the exact form of the active metabolite remains elusive.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: ticlopidine |
|
No information available. |
Summary of Clinical Use |
Ticlopidine is used to prevent blood clots after a recent heart attack or stroke |
Mechanism Of Action and Pharmacodynamic Effects |
Ticlopidine antagonises the P2Y purinoceptor 12 (P2RY12), leading to impaired ADP-mediated activation of the integrin αIIbβ3 complex on platelet membranes which normally binds fibrinogen. This action inhibits fibrinogen-induced aggregation of platelets, thereby reducing clot formation. |
External links |
For extended ADME data see the following: Drugs.com |